156 related articles for article (PubMed ID: 32974905)
1. A class of proportional win-fractions regression models for composite outcomes.
Mao L; Wang T
Biometrics; 2021 Dec; 77(4):1265-1275. PubMed ID: 32974905
[TBL] [Abstract][Full Text] [Related]
2. Stratified proportional win-fractions regression analysis.
Wang T; Mao L
Stat Med; 2022 Nov; 41(26):5305-5318. PubMed ID: 36104953
[TBL] [Abstract][Full Text] [Related]
3. A win ratio approach to the re-analysis of Multiple Risk Factor Intervention Trial.
Kotalik A; Eaton A; Lian Q; Serrano C; Connett J; Neaton JD
Clin Trials; 2019 Dec; 16(6):626-634. PubMed ID: 31389723
[TBL] [Abstract][Full Text] [Related]
4. Weighted win loss approach for analyzing prioritized outcomes.
Luo X; Qiu J; Bai S; Tian H
Stat Med; 2017 Jul; 36(15):2452-2465. PubMed ID: 28343373
[TBL] [Abstract][Full Text] [Related]
5. Sample size formula for general win ratio analysis.
Mao L; Kim K; Miao X
Biometrics; 2022 Sep; 78(3):1257-1268. PubMed ID: 34047366
[TBL] [Abstract][Full Text] [Related]
6. The Average Hazard Ratio - A Good Effect Measure for Time-to-event Endpoints when the Proportional Hazard Assumption is Violated?
Rauch G; Brannath W; Brückner M; Kieser M
Methods Inf Med; 2018 May; 57(3):89-100. PubMed ID: 29719915
[TBL] [Abstract][Full Text] [Related]
7. A generalized analytic solution to the win ratio to analyze a composite endpoint considering the clinical importance order among components.
Dong G; Li D; Ballerstedt S; Vandemeulebroecke M
Pharm Stat; 2016 Sep; 15(5):430-7. PubMed ID: 27485522
[TBL] [Abstract][Full Text] [Related]
8. On recurrent-event win ratio.
Mao L; Kim K; Li Y
Stat Methods Med Res; 2022 Jun; 31(6):1120-1134. PubMed ID: 35345957
[TBL] [Abstract][Full Text] [Related]
9. Analysis of ordered composite endpoints.
Follmann D; Fay MP; Hamasaki T; Evans S
Stat Med; 2020 Feb; 39(5):602-616. PubMed ID: 31858640
[TBL] [Abstract][Full Text] [Related]
10. The win odds: statistical inference and regression.
Song J; Verbeeck J; Huang B; Hoaglin DC; Gamalo-Siebers M; Seifu Y; Wang D; Cooner F; Dong G
J Biopharm Stat; 2023 Mar; 33(2):140-150. PubMed ID: 35946932
[TBL] [Abstract][Full Text] [Related]
11. A win ratio approach for comparing crossing survival curves in clinical trials.
Zheng S; Wang D; Qiu J; Chen T; Gamalo M
J Biopharm Stat; 2023 Jul; 33(4):488-501. PubMed ID: 36749067
[TBL] [Abstract][Full Text] [Related]
12. The asymptotic distribution of the Net Benefit estimator in presence of right-censoring.
Ozenne B; Budtz-Jørgensen E; Péron J
Stat Methods Med Res; 2021 Nov; 30(11):2399-2412. PubMed ID: 34633267
[TBL] [Abstract][Full Text] [Related]
13. The stratified win ratio.
Dong G; Qiu J; Wang D; Vandemeulebroecke M
J Biopharm Stat; 2018; 28(4):778-796. PubMed ID: 29172988
[TBL] [Abstract][Full Text] [Related]
14. The use of the win odds in the design of non-inferiority clinical trials.
Peng L
J Biopharm Stat; 2020 Sep; 30(5):941-946. PubMed ID: 32475213
[TBL] [Abstract][Full Text] [Related]
15. Win ratio approach for analyzing composite time-to-event endpoint with opposite treatment effects in its components.
Liao R; Chakladar S; Gamalo M
Pharm Stat; 2022 Nov; 21(6):1342-1356. PubMed ID: 35766113
[TBL] [Abstract][Full Text] [Related]
16. The win ratio: a new approach to the analysis of composite endpoints in clinical trials based on clinical priorities.
Pocock SJ; Ariti CA; Collier TJ; Wang D
Eur Heart J; 2012 Jan; 33(2):176-82. PubMed ID: 21900289
[TBL] [Abstract][Full Text] [Related]
17. Estimation of treatment effects based on possibly misspecified Cox regression.
Hattori S; Henmi M
Lifetime Data Anal; 2012 Oct; 18(4):408-33. PubMed ID: 22527680
[TBL] [Abstract][Full Text] [Related]
18. Large sample inference for a win ratio analysis of a composite outcome based on prioritized components.
Bebu I; Lachin JM
Biostatistics; 2016 Jan; 17(1):178-87. PubMed ID: 26353896
[TBL] [Abstract][Full Text] [Related]
19. Win statistics (win ratio, win odds, and net benefit) can complement one another to show the strength of the treatment effect on time-to-event outcomes.
Dong G; Huang B; Verbeeck J; Cui Y; Song J; Gamalo-Siebers M; Wang D; Hoaglin DC; Seifu Y; Mütze T; Kolassa J
Pharm Stat; 2023 Jan; 22(1):20-33. PubMed ID: 35757986
[TBL] [Abstract][Full Text] [Related]
20. The win ratio: Impact of censoring and follow-up time and use with nonproportional hazards.
Dong G; Huang B; Chang YW; Seifu Y; Song J; Hoaglin DC
Pharm Stat; 2020 May; 19(3):168-177. PubMed ID: 31671481
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
